​On December 14, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the newly-developed bispecific antibody-receptor recombinant protein drug (project number: IMM2520), targeting CD47 and PD-L1, obtained clinical research approval from the US FDA.

On December 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(hereinafter referred to as "ImmuneOnco") announced that phase II clinical studies of the first domestic SIRPαFc fusion protein targeting human CD47, IMM01，combined with PD-1 monoclonal antibody for solid tumors and lymphomas were officially launched.

On August 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that the newly developed humanized IgG1 CD70 antibody (project number: IMM40H) has been approved by the US FDA and China NMPA for Clinical trial research almost simultaneously.

On August 6, 2022, the Securities Times Biomedical Innovation Forum and the 2nd Drug Innovation Award Ceremony hosted by the Securities Times were held in Shanghai. Chairman founder of ImmuneOnco，Dr.Tian, Wenzhi,, was successfully selected as the "Top Ten Drug Innovation Scientists in 2021", and Drug candidate IMM2902 for Injection won the "Annual Drug Innovation Pioneering Award".

On July 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that the first global CD47×HER2 bispecific molecule (IMM2902) have received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for breast cancer. The grant of FTD by the US FDA is a major affirmation to IMM2902.